Movement Alert|Abivax S.A. After-Hours Rise 4.46% in After-Hours Trading, company rejects short report as inaccurate and misleading

Market Focus
11/21

On November 21, Abivax S.A. rose 4.46% in After-Hours Trading to $74.8/share, with turnover of $837,400.

The move followed the company’s response to a short report published on November 20, stating that the report contained inaccurate and misleading claims and reaffirming the integrity of its clinical development program and Phase 3 ABTECT trial results in ulcerative colitis.

Earlier in Regular Trading, the stock had fallen after Wedbush lowered its price target to $96 from $118 while maintaining a neutral rating. That context highlights how the company’s formal rebuttal appears to have eased some of the pressure tied to the short-seller attack. Abivax S.A.’s lead candidate, obefazimod, is in Phase 3 development for moderately to severely active ulcerative colitis and is also being developed for Crohn’s disease.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10